The invention relates to high affinity human monoclonal antibodies,particularly those directed against isotypic determinants of immunoglobulin E(IgE), as well as direct equivalents and derivatives of these antibodies.These antibodies bind to their respective target with an affinity at least 100fold greater than the original parent antibody. These antibodies are usefulfor diagnostics, prophylaxis and treatment of disease.